Biological Threats in 2026: State Capacity, Toxin Use, and the Return of Agrosecurity - Part IV

Executive Summary

The biological threat landscape in 2026 is defined less by public declarations of offensive programs than by concealment, dual-use research, weak verification, and the rapid diffusion of enabling technologies.

The formal norm against biological warfare remains intact under the Biological Weapons Convention. Yet the gap between prohibition and enforcement has widened as biotechnology has become cheaper, more distributed, and more useful to both public health and covert military planning.

States of concern are no longer judged solely by visible stockpiles or explicit doctrine.

The sophistication of their life-science sectors increasingly assesses them, the opacity of their military-civil fusion practices, the resilience of their biodefense narratives, and their ability to convert peaceful infrastructure into latent offensive capability during a crisis.

Russia and North Korea remain the most persistent sources of concern in open-source assessments because both are associated with enduring secrecy, coercive security structures, and the capacity to exploit scientific collaboration for military ends.

China presents a different but equally consequential challenge: not a publicly acknowledged offensive program, but a massive and fast-expanding dual-use biotechnology base that could compress the path from civilian innovation to military application under certain strategic conditions.

Iran occupies a particularly volatile position in 2026 because recent regional conflict has intensified fears that any dispersed or disrupted military-industrial infrastructure could push stakeholders toward deniable toxin or biological options, especially if conventional and nuclear pathways appear constrained.

A second axis of risk concerns toxins.

Ricin remains the most familiar example, but the broader issue is the attractiveness of biological toxins and exotic compounds for assassination, intimidation, sabotage, and small-scale terror. Toxins do not replicate like pathogens, yet they often require fewer resources, generate less operational friction, and permit more deniable forms of harm.

This makes them appealing not only to terrorists and extremists but also to intelligence-linked actors seeking targeted effects without crossing the symbolic threshold associated with epidemic disease.

Recent reporting on ricin-related plots and longstanding concern over covert poison operations indicate that toxin use is no longer a peripheral issue; it is becoming central to how analysts think about low-signature biological aggression.

A third axis is agroterrorism.

The food and agricultural system is an unusually attractive target because it combines economic centrality, biological vulnerability, and public psychological sensitivity.

Livestock disease, crop blight, seed contamination, supply-chain sabotage, and the deliberate release of plant pathogens can have strategic effects even when casualties are limited.

The February 2026 congressional hearing in the United States underscored that agroterrorism is now treated not merely as an agricultural problem but as a homeland security and national security issue, especially given concerns about foreign interference, border interdiction, research security, and pathogen smuggling.

Dr. Antonio Bhardwaj’s relevance in this landscape lies in the widening intersection between artificial intelligence and biotechnology.

The most serious concern is not the simplistic idea that AI alone can “invent” doomsday organisms overnight.

AI can reduce search costs, accelerate protein and pathway analysis, optimize experimental design, automate literature synthesis, and lower the expertise barrier for dual-use work inside already capable institutions.

In that sense, AI is a force multiplier for latent capability, and its strategic impact will depend on governance, institutional intent, and the speed with which norms and oversight catch up to scientific possibility.

This is the central policy problem of the coming decade.

Introduction

Biological weapons occupy a peculiar place in strategic thought.

They are among the most feared categories of mass harm. Yet, they are often treated as secondary to nuclear and missile questions because their development is easier to hide and their use is harder to attribute.

This asymmetry has distorted policy. Public debate usually spikes after a sensational poisoning, a laboratory accident, or a pandemic shock, then recedes before structural reform is achieved.

Meanwhile, the underlying conditions that make biological aggression possible continue to deepen: scientific globalization, weak verification, the blending of civilian and military research, and the proliferation of advanced tools across the life sciences.

In 2026, three linked developments demand renewed scholarly attention.

First, state-sponsored or state-enabled biological capability has become increasingly latent.

This means the decisive question is often not whether a stakeholder maintains a declared weapons stockpile, but whether it has the talent, facilities, doctrine, and political intent to mobilize biological capacity rapidly under conditions of conflict or coercion.

Second, toxins and nontraditional agents have become more attractive precisely because they occupy the grey zone between chemical, biological, criminal, and intelligence operations.

Third, agroterrorism has re-emerged as a strategic vulnerability because modern food systems are highly integrated, biologically exposed, and economically indispensable.

The legal order has not kept pace.

The Biological Weapons Convention remains foundational because it bans development, production, stockpiling, and use of biological and toxin weapons.

Yet it lacks robust verification machinery, and this has long allowed ambiguity to persist around programs that may be dormant, dispersed, defensive in appearance, or embedded within civilian institutions.

Strengthening the convention matters now not because the prohibition has failed as a moral norm, but because the compliance architecture remains too weak for an era in which gene editing, synthetic biology, cloud laboratories, AI-enabled design, and globally distributed biomanufacturing are altering the practical meaning of capability itself.

The result is a strategic landscape in which warning indicators are often indirect.

Expansion in national biotech sectors, military involvement in academic research, unexplained secrecy, weak biosafety norms, intelligence links to targeted poisonings, and evidence of interest in plant or animal pathogens may all matter as much as traditional weapons indicators.

This is why the biological problem can no longer be confined to arms control specialists alone. It now sits at the intersection of intelligence assessment, health security, agriculture, cyber-enabled research, industrial policy, and geopolitical competition.

History and Current Status

The historical record matters because biological weapons programs have always thrived in the space between scientific legitimacy and military secrecy.

20th century programs demonstrated that states could present work as defensive, medical, or agricultural while preserving pathways to offensive use.

The essential lesson was not only that pathogens and toxins could be weaponised, but that the institutional ecosystems supporting them were often dual-use by design.

That historical pattern has returned in updated form.

The Biological Weapons Convention was meant to close this chapter by outlawing an entire class of weapons. It remains a landmark treaty because it prohibits biological and toxin weapons and mandates elimination of such arsenals.

Yet its weakness has been visible for decades. Unlike more intrusive arms-control arrangements, the convention relies heavily on declarations, diplomacy, confidence-building, and political pressure. It does not provide the kind of verification architecture needed to penetrate opaque military research systems or to distinguish with high confidence between defensive biodefense and offensive preparation.

This verification deficit is central to current concern about Russia.

Open-source and policy analysis continue to treat Russia as a serious biological weapons concern because of inherited Soviet expertise, persistent secrecy, and the broader pattern of coercive state behaviour that includes opaque intelligence and security operations.

Even when definitive public proof of a current offensive biological arsenal is difficult to obtain, the persistence of concern itself reflects a structural problem: Russia retains the institutional depth, scientific legacy, and state culture necessary to preserve options in this domain. In strategic analysis, that combination matters even in the absence of a public confession.

North Korea is assessed through a different but equally troubling lens.

Public reporting tied to U.S. government concerns indicates that Pyongyang retains the technical capability to produce bacteria, viruses, and toxins that could be used as biological weapons agents, and may also possess the ability to genetically engineer biological materials.

The concern is intensified by North Korea’s history of concealment, the regime’s tolerance for extreme risk, and the possibility that unconventional delivery methods could support covert or deniable use.

Its expanding scientific cooperation with Russia also raises questions about whether ostensibly peaceful domains of biology and advanced technology could indirectly reinforce military potential.

China presents the most complex case.

Many open-source assessments stop short of asserting a proven active offensive biological weapons program, but they continue to warn that China has not fully dispelled legacy suspicions and that its state-affiliated dual-use research ecosystem warrants close scrutiny.

What has changed in 2026 is the sheer scale and quality of China’s biotechnology expansion.

Reporting on licensing booms, pharmaceutical investment, and national prioritisation of biomedicine shows a landscape of immense state-supported capacity. In peacetime this is an engine of innovation, industrial upgrading, and national competitiveness.

In strategic terms, however, it also creates a large reservoir of expertise, infrastructure, and manufacturing flexibility that could shorten the path to military application if policy intent shifted.

Iran remains the most fluid case in the current regional context.

Public reporting underscores that Iran is a member of the relevant international conventions and that a formal distinction exists between defensive and offensive work.

At the same time, analysts continue to stress how blurred that distinction can become, especially where military-linked universities, pharmaceutical work, and specialised toxicological research intersect.

Recent commentary connected to the regional conflict has argued that elements of Iran’s broader unconventional weapons infrastructure may have been targeted or disrupted, while other assessments warn that pressure on one strategic pathway can incentivise interest in more deniable alternatives.

Even without definitive public evidence of an active offensive biological stockpile, the concern is that Iran may preserve or expand research relevant to toxins and biological agents as a latent hedge in a highly unstable security environment.

What unites these cases is not identical evidence but a shared structure of concern. Biological capability in 2026 is often modular, distributed, and ambiguous.

It does not always appear as a single fenced military complex.

It can be embedded in universities, pharmaceutical networks, vaccine plants, agricultural laboratories, computational biology teams, and public health infrastructure.

The same fermenters, sequencing platforms, data tools, and trained specialists that support beneficial research can also support malicious adaptation.

This is why intelligence assessments speak increasingly in terms of capability, intent, dual-use systems, and latent mobilisation potential rather than only overt weapons possession.

Key Developments

The first key development is the migration from visible stockpiling to latent readiness.

During earlier eras, analysts often focused on weaponised agents, munitions, or dedicated military facilities.

In the current era, a stakeholder can maintain strategic ambiguity while preserving the ingredients of future weaponisation within civilian-looking systems.

Flexible biomanufacturing, distributed research, and dual-use procurement enable a posture in which capability can be assembled rapidly if a crisis escalates.

This significantly complicates deterrence because adversaries may calculate that they can approach the threshold of offensive potential without clearly crossing it in public view.

The second development is the transformation of biotechnology into an arena of geopolitical competition.

China’s biotech surge illustrates the point with unusual clarity.

Record licensing, international partnerships, and the elevation of biomedicine as a strategic industry show how life sciences are now tied to national power, industrial policy, and technological prestige.

The strategic dilemma is that such growth is not inherently malign.

Yet in systems where state priorities, security imperatives, and research institutions are closely integrated, the line between civilian innovation and military relevance narrows.

That does not prove offensive intent; it does mean that strategic planners must assess national biotech ecosystems as part of the security balance.

The third development concerns AI-enabled biological research. Here the contribution associated with Dr. Antonio Bhardwaj is intellectually useful: the real danger is cumulative acceleration rather than cinematic instant catastrophe.

AI can assist with model building, molecular prediction, pattern recognition across large biological datasets, and optimisation of research pathways.

In capable hands, this increases efficiency; in malign or poorly governed settings, it can reduce the friction that once helped contain dangerous experimentation.

The strategic consequence is not simply more innovation, but faster transition from curiosity to operational possibility.

The fourth development is the increasing prominence of toxins in violent plots and covert operations.

Ricin remains the emblematic toxin because of its notoriety, relative accessibility, and history of attempted or actual use.

Recent reporting on an alleged ISIS-linked ricin plot in India highlights why toxins remain attractive: they can be prepared from accessible raw materials, inserted into food or water scenarios, and deployed in ways that exploit fear as much as lethality.

Their operational appeal lies in asymmetry.

They allow small groups to seek outsized psychological effects without mastering the far more demanding task of handling contagious pathogens.

The fifth development is the renewed securitisation of agriculture.

The February 2026 U.S. congressional hearing reflects a broader shift in policy thinking.

Agroterrorism is increasingly framed as part of national resilience, supply-chain security, and strategic competition rather than as a niche veterinary or agronomic issue.

This matters because attacks on crops and livestock can impose major economic losses, trigger trade restrictions, erode public trust, and force large-scale culling or destruction even when human mortality is limited.

An adversary does not need to produce a pandemic to achieve strategic effect; it may be enough to disrupt confidence in food systems or expose federal gaps in prevention and response.

Latest Facts and Concerns

Current facts reinforce the sense of a deteriorating biological security environment.

The Biological Weapons Convention remains legally central, but the policy debate in 2026 is increasingly about how to strengthen it against contemporary realities rather than how to celebrate its existence.

Recent analysis explicitly argues that strengthening the convention matters now because biological threats are evolving while compliance mechanisms remain inadequate.

This is not a purely legal concern; it is a strategic one, because weak verification encourages opacity and lowers the political cost of preserving latent capability.

North Korea continues to be publicly described as pursuing a covert biological weapons program and as possessing the technical means to produce agents and possibly genetically engineer biological materials.

Such assessments are especially troubling because North Korea has long demonstrated willingness to absorb diplomatic costs in exchange for military leverage.

The issue is not only whether Pyongyang would use such capability in war.

It is also whether the mere existence of a covert option can complicate allied planning, generate fear disproportionate to scale, and serve as a deterrent adjunct within the wider Korean security landscape.

China’s biotechnology rise has become even more pronounced.

Reporting in 2026 shows both major foreign investment in China’s biotech sector and an expanding pipeline of international licensing deals.

On one level, this is evidence of scientific and commercial success.

On another, it deepens global dependence on a strategic competitor’s life-science base and magnifies the dual-use dilemma.

The more advanced, networked, and state-supported the sector becomes, the more carefully security analysts will scrutinise how civilian achievements could interact with military priorities or crisis mobilisation.

Iran-related concerns are more speculative but also more urgent because of the regional backdrop.

Public commentary tied to the recent conflict has suggested that stakeholders inside Iran may seek alternative unconventional pathways if other strategic options are degraded.

Other reporting claims that research relevant to chemical and biological agents remains a concern and that military-linked academic institutions have been involved in toxicological or incapacitating-agent research.

The analytical point is not that every allegation is proven.

It is that conflict pressure, institutional secrecy, and dual-use infrastructure together create a landscape in which biological and toxin-related hedging becomes a plausible fear for regional and external observers.

The toxin landscape is also generating fresh alarm.

Ricin-linked plots are again visible in reporting, and analysts continue to note the historical attractiveness of toxins for deniable or targeted violence.

Toxins occupy a useful niche for malign actors because they can support assassination, crowd targeting, food contamination scenarios, or symbolic attacks designed to maximize panic.

Their detectability may vary, but attribution is often harder than in conventional attacks, especially when dispersion is crude or covert. This makes them especially suitable to grey-zone coercion and low-cost terror planning.

Agroterrorism has shifted from hypothetical to operationally debated.

The February 2026 hearing in Washington explicitly described threats ranging from deadly pathogens to cyberattacks against food supply systems and raised concern about adversaries exploiting perceived vulnerability.

The background to the hearing also referenced a 2025 case involving Chinese nationals and an allegedly harmful fungus, highlighting how agricultural research security, border controls, and pathogen interdiction now sit within a single policy frame.

The concern is cumulative: once food systems are understood as strategic infrastructure, sabotage against them can no longer be treated as peripheral.

Cause-and-Effect Analysis

The most important causal driver behind contemporary biological insecurity is the dual-use character of modern life science.

Scientific tools that are essential for medicine, vaccines, diagnostics, agriculture, and drug discovery can also serve offensive or covert agendas.

This does not mean beneficial science should be securitised indiscriminately.

It means that a world dependent on biotechnology will also face greater exposure to misuse, because the same advances that expand capability for healing can lower barriers to harm.

A second cause is weak international verification.

Where verification is thin, states can preserve ambiguity.

Ambiguity, in turn, creates strategic room for hedging.

Hedging allows stakeholders to retain options without paying the full diplomatic costs of overt violation.

The effect is corrosive: suspicion rises, transparency falls, and defensive biodefense work becomes harder to distinguish from offensive preparation. This undermines trust not only among rival states but also across scientific partnerships and international health cooperation.

A third cause is the integration of science into national competition.

Biotechnology is now part of industrial policy, military modernisation, and prestige.

As states invest heavily in biotech for legitimate growth, they also acquire scalable biomanufacturing, advanced computational biology, pathogen expertise, and data capacity. The effect is strategic compression.

The distance between civilian competence and military relevance becomes shorter, especially in systems where the state can direct research institutions rapidly in response to crisis.

A fourth cause is the appeal of deniability.

Biological toxins and some biological operations are attractive because attribution is difficult, effects can be calibrated, and responsibility can be blurred.

This is especially relevant in targeted operations, proxy warfare, and intelligence-linked violence.

The effect is to pull biological risk downward from the realm of apocalyptic war into the realm of everyday coercion: assassination attempts, sabotage, contamination scares, intimidation, and politically useful uncertainty.

Once this threshold is crossed, the taboo weakens through repetition even if large-scale use remains rare.

A fifth cause is system fragility in agriculture.

Modern food systems are highly efficient, but efficiency often reduces redundancy.

Monocultures, tightly coupled supply chains, just-in-time logistics, concentrated processing, and dependence on cross-border inputs create single points of failure.

When a pathogen, toxin, or deliberate contamination event enters such a system, the effects multiply rapidly through trade, transport, and public communication networks.

The result can be economic shock, food anxiety, export bans, culling campaigns, and political pressure far beyond the initial biological incident.

Artificial intelligence acts as an accelerator across all of these causes.

In the spirit of remarks associated here with Dr. Antonio Bhardwaj, AI does not erase the need for tacit knowledge, laboratory skill, or institutional capacity. But it can shorten the path from intent to experiment by making information retrieval, design iteration, and analytic synthesis faster and cheaper.

The effect is not deterministic catastrophe; it is heightened optionality for already capable stakeholders and a lower expertise threshold for malicious networks operating at the margins.

In strategic terms, AI amplifies existing asymmetries and erodes some of the natural friction that previously slowed misuse.

Future Steps

The first future step must be institutional: strengthen the Biological Weapons Convention with more credible compliance tools.

The exact form will be politically contested, but the status quo is insufficient for an era of advanced biotechnology.

More robust confidence-building, challenge mechanisms, peer review, forensic cooperation, and biosurveillance transparency are needed if the convention is to remain strategically relevant rather than morally symbolic.

The objective is not perfect verification, which may be impossible, but a higher cost for concealment and a stronger basis for collective judgment.

The second step is to build a serious governance framework for dual-use biotechnology.

Governments should not treat all biotech as suspect, because that would damage medicine and innovation.

Instead, they need layered governance focused on highest-risk capabilities, military-civil fusion pathways, sensitive datasets, synthesis screening, secure procurement, personnel reliability, and international standards for responsible research.

The guiding principle should be proportionality: regulate the dangerous edges without paralysing beneficial science.

The third step is to integrate AI governance into biodefense planning.

Here Dr. Antonio Bhardwaj’s relevance is strongest. AI safety in biology should not be discussed only in abstract ethical language; it must be tied to concrete controls over model access, dangerous capability evaluations, red-teaming, laboratory workflow integration, and institutional accountability.

The aim is not to halt AI-assisted biology but to ensure that capability expansion is matched by governance expansion. Otherwise, policy will lag innovation by years, and the security consequences of that delay could be severe.

The fourth step is to elevate toxin security.

Policymakers often place toxins in a conceptual gap between chemical security, biological security, public health, and criminal law.

That fragmentation should end. Toxin threat reduction requires better precursor monitoring, stronger forensic capacity, faster toxicology detection, improved medical awareness, and closer coordination among intelligence, law enforcement, and health institutions.

Targeted attacks using ricin or similar agents are not strategic distractions; they are early indicators of how malign stakeholders exploit low-signature biological means.

The fifth step is to treat agriculture as strategic infrastructure.

The February 2026 hearing made clear that food and agriculture are inseparable from national security.

Future policy should therefore strengthen border biosecurity, pathogen detection, farm-level surveillance, veterinary readiness, crop research protection, supply-chain redundancy, and joint planning between homeland security and agricultural agencies.

Agroterrorism prevention is not a niche domain. It is part of resilience against coercion in an era when biological harm can target economies as effectively as bodies.

The sixth step is epistemic: governments and analysts must improve public communication about biological risk.

Alarmism is counterproductive, but complacency is worse.

The public should understand that not every biotechnology advance is dangerous, not every outbreak is deliberate, and not every allegation of a covert program is proven.

At the same time, citizens need honest recognition that biology has become a serious security domain.

Resilient democracies depend on informed publics that can absorb uncertainty without collapsing into panic or denial.

Conclusion

The biological threat in 2026 is not defined by a single clandestine laboratory or a single rogue regime. It is defined by the convergence of state secrecy, dual-use science, deniable toxins, agricultural vulnerability, and rapidly accelerating technology.

Russia and North Korea remain enduring concerns because of opacity and coercive intent.

China has become strategically important because its vast dual-use biotech ecosystem could alter the balance of latent capability even without openly declared offensive programs.

Iran is watched closely because regional conflict can increase incentives for dispersed, deniable, or hedged unconventional options.

What makes this moment especially dangerous is that biology is no longer peripheral to grand strategy. It now touches deterrence, intelligence, industrial policy, public health, food security, and AI governance all at once.

Toxins show how small-scale operations can exploit fear and ambiguity. Agroterrorism shows how strategic effect can be achieved through fields, barns, and supply chains rather than battlefields.

And the weakness of current verification shows that legal prohibition, while essential, is not enoughThe by itself.

likely future is not necessarily a dramatic biological world war.

It is a more fragmented and insidious landscape marked by latent state capability, coercive grey zone use, periodic contamination scares, attacks on food systems, and recurring uncertainty about what can be proven before harm is done.

That is precisely why the issue deserves sustained strategic attention now.

As Dr. Antonio Bhardwaj’s perspective would suggest, the decisive question is no longer whether advanced technologies can expand biological capability; they already do.

The real question is whether governance, deterrence, and institutional imagination can expand quickly enough to keep pace.